Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VNDA vs ACRS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VNDA Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–4 Matrix Metrics)

VNDA Overall Winner 6-Pillar Tally: VNDA 5 – 0 ACRS (1 Tie) Matrix Metrics: VNDA 6 – 4 ACRS

As of Nov 16, 2026, Vanda Pharmaceuticals Inc. (VNDA) is the stronger overall head-to-head candidate over Aclaris Therapeutics, Inc. (ACRS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas ACRS carries 38.7/100 (SELL) at $3.65 (N/M Forward P/E, -1412.4% operating margin).

  • Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile ACRS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VNDA vs ACRS
VNDA NASDAQ Head-to-Head Winner
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
TTM Revenue $229M
Forward P/E 103.1x
Beta / 30D Vol 1.25β · 61% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.9%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $3.95 · SMA50: $4.46
ACRS NASDAQ
Aclaris Therapeutics, Inc.
Pharmaceutical Preparations
$3.65
-7.02% 1D
Market Cap $620.2M
TTM Revenue $6.4M
Forward P/E N/M
Beta / 30D Vol 1.53β · 73% Vol
Unified Composite Score
38.7 / 100 SELL
Tech 25.0 Fund 50.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.9%), weak momentum, RSI 41
RSI-14: 40.5 · SMA20: $3.88 · SMA50: $4.38

6-Pillar Scorecard Institutional Category Breakdown (VNDA 5 – 0 ACRS)

Columns: Metric · VNDA · ACRS
1. Valuation Multiples VNDA
Forward P/E 103.1x N/M
Trailing P/E 103.1x N/M
PEG Ratio 2.23x N/M
EV / Revenue 0.9x 96.9x
2. Growth & Scale VNDA
Revenue Growth (YoY) +24.1% -55.1%
Earnings Growth (YoY) -95.9% +0.0%
TTM Revenue (USD) $229M $6.4M
Market Cap $238.9M $620.2M
3. Profitability & Quality VNDA
Gross Margin 93.6% N/A
Operating Margin -77.6% -1412.4%
Net Profit Margin -119.9% 0.0%
Return on Equity (ROE) -82.5% -55.5%
4. Balance Sheet & Cash Flow VNDA
Cash Generation (TTM) -$150M -$75M
Cash Flow Margin -65.4% N/A
Net Cash / Leverage $40M Net Cash $1.11 Book/Sh · -55.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VNDA
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 163.3% (75th %ile) 60.7% (1st %ile)
Put/Call OI Skew N/A 8.77x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VNDA (6) vs ACRS (4)
Institutional Metric VNDA ACRS Criterion Row Edge
Market Capitalization
Scale
$238.9M $620.2M Larger Scale ACRS
Trailing P/E Ratio
Valuation
103.1x N/M Lower Multiple VNDA
Forward P/E Ratio
Valuation
103.1x N/M Lower Multiple VNDA
Revenue Growth (YoY)
Growth
+24.1% -55.1% Higher Growth VNDA
Operating Margin (TTM)
Profitability
-77.6% -1412.4% Higher Margin VNDA
Net Profit Margin
Profitability
-119.9% 0.0% Higher Margin ACRS
Return on Equity (ROE)
Capital Efficiency
-82.5% -55.5% Higher ROE ACRS
52-Week Range Position
Momentum
4% ($4–$10) 32% ($2–$7) Stronger Trend ACRS
Beta / 30D Volatility
Risk Regime
1.25β · 61% Vol 1.53β · 73% Vol Lower Realized Risk VNDA
Unified Institutional Score
Composite Signal
49.0 / 100 (HOLD) 38.7 / 100 (SELL) Higher Composite VNDA
Trailing 12M Revenue (USD)
Operating Scale
$229M $6.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
93.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.23x PEG · 0.9x EV/Rev N/M PEG · 96.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$150M ($40M Net Cash) -$75M ($1.11 Book/Sh · -55.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACRS +16.96 pp
VNDA: -5.83% · ACRS: +11.13%
3M Horizon VNDA +11.95 pp
VNDA: -30.24% · ACRS: -42.19%
6M Horizon ACRS +20.42 pp
VNDA: -37.58% · ACRS: -17.16%
1Y Horizon ACRS +69.67 pp
VNDA: -12.56% · ACRS: +57.11%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VNDA Revenue ACRS Revenue VNDA Op. Margin ACRS Op. Margin Margin Leader
FY2018 $190M $10M 11.3% -1378.3% VNDA
FY2019 $230M $0M 10.0% -2627.3% VNDA
FY2020 $250M $10M 11.0% -785.4% VNDA
FY2021 $270M $10M 15.7% -1327.1% VNDA
FY2022 $250M $30M 2.5% -302.0% VNDA
FY2023 $190M $30M -7.2% -311.6% VNDA
FY2024 $200M $20M -20.5% -758.2% VNDA
FY2025 $220M $10M -70.0% -975.9% VNDA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VNDA BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 163.3%
IV Percentile 75th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACRS BREAKDOWN
129d in phase · OBV NEUTRAL
Current IV 60.7%
IV Percentile 1st %ile
Put/Call OI Skew 8.77x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ACRS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VNDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACRS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $620.2M market capitalization and -1412.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VNDA vs ACRS Key Questions & Quantitative Answers

As of Nov 16, 2026, Vanda Pharmaceuticals Inc. (VNDA) is the stronger overall head-to-head candidate over Aclaris Therapeutics, Inc. (ACRS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VNDA carries a Unified Composite Score of 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin), whereas ACRS carries 38.7/100 (SELL) at $3.65 (N/M Forward P/E, -1412.4% operating margin). Technical & Structure Timing Caution: VNDA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0); meanwhile ACRS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VNDA leads the Growth & Scale pillar: VNDA posts +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin), compared with ACRS at -55.1% YoY revenue growth and +0.0% YoY earnings growth on $6.4M TTM revenue (N/A gross margin, -1412.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VNDA cumulative revenue shifted +15.8% while ACRS shifted +0.0%. In operating R&D and SG&A reinvestment, VNDA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ACRS.

VNDA screens cheaper on headline valuation multiples. VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin), whereas ACRS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 96.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VNDA (-82.5% ROE) versus ACRS (-55.5% ROE) capital efficiency.

In options market volatility and institutional positioning, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk). By comparison, ACRS carries 60.7% implied volatility (1st %ile, Compressed (<25th %ile)), a 8.77x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.53β · 73% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.